• 首页
  • 关于期刊
    期刊简介
    编委会
    青年编委会
    合作单位
    《药学研究》编辑部
  • 投稿指南
  • 制度与声明
    出版伦理规范
    学术不端声明
    开放获取(OA)声明
    AIGC工具使用声明
  • 期刊订阅
  • 下载中心
  • English
引用本文:陈辉,邱丽丽,丁菊英.老年住院患者注射用红花黄色素超说明书用药分析及干预[J].药学研究,2020,39(5):304-307[点击复制]
【打印本页】      【下载PDF全文】   【查看/发表评论】  【下载PDF阅读器】  【关闭】
←前一篇|后一篇→ 过刊浏览    高级检索
本文已被:浏览 3316次   下载 2977次 本文二维码信息
码上扫一扫!
老年住院患者注射用红花黄色素超说明书用药分析及干预
陈辉1,邱丽丽2,丁菊英2
字体:加大+|默认|缩小-
(1.武警特色医学中心药材科,天津 300162;2.胜利油田中心医院药学部,山东 东营 257034)
摘要:
目的 分析老年住院患者注射用红花黄色素超说明书用药情况并干预,降低老年人用药风险,促进临床合理使用。方法 分析老年住院患者注射用红花黄色素超说明书用药现状,通过对其超说明书用药的临床研究和文献进行检索评价后,制定注射用红花黄色素超说明书用药规则,采取软件智能审核与临床药师审核互补的方式对超说明书用药情况进行点评干预。随机抽取2018年1-6月(干预前)和2018年7~12月(干预后)老年住院患者使用注射用红花黄色素病历各480份,评价超说明书用药干预效果。结果 老年住院患者超说明书使用注射用红花黄色素问题严重。涉及的超说明书用药类型主要有超适应症用药、超溶媒、配伍禁忌和超注意事项,干预后各类型超说明书用药例数均明显下降,超说明书用药医嘱比例由干预前的56.61%下降至16.21%,不良反应上报数量由干预前的8例降至干预后的3例。结论 老年住院患者注射用红花黄色素超说明书用药情况普遍存在,利用合理用药软件实时监测与临床药师审核互补的方式可以显著减少超说明书用药。
关键词:  注射用红花黄色素  超说明书用药  老年患者  干预
DOI:10.13506/j.cnki.jpr.2020.05.013
基金项目:山东省中医药科技发展计划项目(No.2015-405、2017-365);东营市中医药重点专科建设项目
Analysis and intervention of the off label use of safflor yellow injection in elderly inpatients
CHEN Hui1,QIU Lili2,DING Juying2
(1.Department of Pharmacy,Characteristic Medical Center of PAP,Tianjin 300162,China;2.Department of Pharmacy,Central Hospital of Shengli Oil Field,Dongying 257034,China)
Abstract:
Objective To analyze and intervene the off-label use of safflor yellow injection in elderly inpatients, and to reduce the risk of drug use and promote its appropriate use.Methods The current situation of the off-label use of safflor yellow injection in elderly inpatients was analyzed. Clinical researches and literature reviews on off-label use of safflor yellow injection were searched and evaluated systematically, and then its reasonable medication rules were developed. To evaluate and intervene the drug use by using a rational drug use software management system audit automatically and clinical pharmacist audit manually. A total of 480 cases of inpatients of safflor yellow injection used from January-June in 2018 (before intervention) and from July-December in 2018 (after intervention) was taken randomly to evaluated the intervention effect on its off-label use.Results Off-label use of safflor yellow injection was serious. The types of off-label use were mainly focused on over indication, over solvent, contraindication and over precaution, after intervention, the situation of off-label use decreased significantly, the proportion of off-label use decreased from 56.61% before intervention to 16.21%, and the number of adverse reactions reported decreased from 8 cases before intervention to 3 cases after intervention.Conclusion Although off-label use of safflor yellow injection was serious, the complementary way of rational drug use software informatized real-time monitoring and clinical pharmacist audited manually may be utilized to reduce the phenomenon.
Key words:  Safflor yellow injection  Off-label usr  Elderly patients  Intervention
今日访问量:2341    总访问量:55338715
网站版权:《药学研究》编辑部     鲁ICP备17018036号-3     鲁公网安备 37010202001351号
主办:山东省食品药品检验研究院、山东省药学会 地址:山东省济南市高新区新泺大街2749号 邮政编码:250101
电话:0531-81216586 电子邮箱:yaoxueyanjiu@163.com;yaoxueyanjiu@126.com
技术支持:北京勤云科技有限公司